Role of sacubitril-valsartan in arrhythmic events and risk of sudden cardiac death in heart failure patients

Authors: Golukhova E.Z., Gromova O.I.

Company: Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russian Federation

For correspondence:  Sign in or register.

Type:  Editorial article


DOI: https://doi.org/10.24022/1997-3187-2022-16-4-427-430

For citation: Golukhova E.Z., Gromova O.I. Role of sacubitril-valsartan in arrhythmic events and risk of sudden cardiac death in heart failure patients. Creative Cardiology. 2022; 16 (4): 427–30 (in Russ.). DOI: 10.24022/1997-3187-2022-16-4-427-430

Received / Accepted:  21.12.2022 / 28.12.2022

Keywords: sacubitril-valsartan heart failure sudden cardiac death meta-analysis

Full text:  

 

Abstract

Sacubitril-valsartan has been proven to reduce the risks of death and hospitalization in patients with heart failure. The pathophysiological mechanisms of heart failure progression and development of atrial and ventricular arrhythmias are largely similar. The research of potential antiarrhythmic effect of sacubitril-valsartan is a very promising direction. In 2022, a major meta-analysis was published on the comparison of atrial and ventricular arrhythmic events and the development of sudden cardiac death in patients on sacubitril-valsartan compared with therapy with angiotensin converting enzyme inhibitors or sartans. The article presents an overview of meta-analysis, as well as possible causes of the antiarrythmic effect of sacubitril-valsartan.

References

  1. Zeppenfeld K., Tfelt-Hansen J., de Riva M., Winkel B.G., Behr E.R., Blom N.A. et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC). Eur. Heart J. 2022; 43 (40): 3997–4126. DOI: 10.1093/eurheartj/ehaC262
  2. Shen L., Jhund P.S., Petrie M.C., Claggett B.L., Barlera S., Cleland L.G.F. et al. Declining risk of sudden death in heart failure. N. Engl. J. Med. 2017; 377: 41–51. DOI: 10.1056/NEJMoa1609758
  3. McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2021; 42 (36): 3599–726. DOI: 10.1093/eurheartj/ehab368
  4. Rohde L.E., Chatterjee N.A., Vaduganathan M., Claggett B., Packer M., Desai A.S. et al. Sacubitril/Valsartan and sudden cardiac death according to implantable cardioverter-defibrillator use and heart failure cause: a PARADIGM-HF analysis. J. Am. Coll. Cardiol. HF. 2020; 8: 844–55. DOI: 10.1016/j.jchf.2020.06.015
  5. Liu X.-H., Wang G.-L., Xu Q., Zhang L., Liu H.J. Effect of sacubitril/valsartan on the occurrence of cardiac arrhythmias and the risk of sudden cardiac death in heart failure: a meta-analysis of randomized controlled trials. Cardiovasc. Med. 2022; 9: 943377. DOI: 10.3389/fcvm.2022.94337

About Authors

  • Elena Z. Golukhova, Dr. Med. Sci., Professor, Academician of Russian Academy of Sciences, Director; ORCID
  • Ol’ga I. Gromova, Cand. Med. Sci., Researcher ORCID

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery